EUVIMEDEUVIMED entdecken
Crossref

Psoriasis Remission in an Obese, Non-Diabetic Patient with Hyperinsulinemia Treated with GLP-1 Receptor Agonist Therapy

Anna Bowling, Christina M Bear, Joshua R Cook, Lindsey A Bordone

Journal of Dermatology Research · 13.07.2026 · 7 (2) · 1-5

DOI: 10.46889/jdr.2026.7209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Dermatology Research, online erschienen am 13.07.2026. Verfasst von Anna Bowling und 3 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psoriasis is a chronic immune-mediated inflammatory skin disease increasingly linked to metabolic dysfunction, including obesity and insulin resistance. While Glucagon-Like Peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes mellitus and obesity, emerging evidence suggests they may also improve psoriasis, primarily in patients with diabetes. Their role in non-diabetic individuals remains unclear. We report a case of a 36-year-old man with obesity and chronic plaque psoriasis who achieved marked and reproducible disease improvement with semaglutide therapy despite normal glycemic indices. The patient had a history of psoriasis previously controlled on biologic therapy but sought alternative treatment due to concerns about long-term immunosuppression. Laboratory evaluation demonstrated hyperinsulinemia and features of metabolic syndrome in the absence of diabetes. Following initiation and titration of semaglutide, the patient experienced significant weight loss and near complete clearance of psoriatic plaques off of biologic therapy. Notably, psoriasis flared during periods of treatment interruption and improved again upon reinitiation of therapy, suggesting a reproducible pharmacologic effect. Reduction in fasting insulin levels paralleled clinical improvement, while glycemic parameters remained largely unchanged. This case highlights insulin resistance and metabolic inflammation as potentially modifiable drivers of psoriasis independent of glycemic control. GLP-1 receptor agonists may offer a novel therapeutic approach in select patients by addressing both metabolic dysfunction and cutaneous disease. Further investigation is warranted to define the mechanisms underlying these effects and to identify patient populations most likely to benefit.

Zitieren

APA

Bowling, A., Bear, C. M., Cook, J. R., & Bordone, L. A. (2026). Psoriasis Remission in an Obese, Non-Diabetic Patient with Hyperinsulinemia Treated with GLP-1 Receptor Agonist Therapy. Journal of Dermatology Research, 7(2), 1-5. https://doi.org/10.46889/jdr.2026.7209

Vancouver

Bowling A, Bear CM, Cook JR, Bordone LA. Psoriasis Remission in an Obese, Non-Diabetic Patient with Hyperinsulinemia Treated with GLP-1 Receptor Agonist Therapy. Journal of Dermatology Research. 2026;7(2):1-5. doi:10.46889/jdr.2026.7209

BibTeX
@article{Bowling2026,
  author = {Bowling, Anna and Bear, Christina M and Cook, Joshua R and Bordone, Lindsey A},
  title = {Psoriasis Remission in an Obese, Non-Diabetic Patient with Hyperinsulinemia Treated with GLP-1 Receptor Agonist Therapy},
  journal = {Journal of Dermatology Research},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {1--5},
  doi = {10.46889/jdr.2026.7209}
}
Kostenlos starten →